Ver­tex lav­ish­es $80M cash to ex­pand gene ther­a­py tool kit; Su­per­nus bags a $300M CNS port­fo­lio

Ver­tex’s bull­ish out­look wasn’t just man­i­fest­ed in its up­beat re­vi­sion of the full-year guid­ance. Ear­li­er this week, the Boston biotech hand­ed over $80 mil­lion in cash to gene ther­a­py up­start Affinia to en­gi­neer new AAV cap­sids to de­liv­er a string of po­ten­tial new treat­ments for Duchenne mus­cu­lar dy­s­tro­phy, my­oton­ic dy­s­tro­phy type 1 and cys­tic fi­bro­sis. Affinia, which de­buted to the biotech world just a month ago with AveX­is vet­er­an Rick Mo­di at the helm, is el­i­gi­ble for $1.6 bil­lion in mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA